No Data
No Data
CRISPR, Beam, Other Gene Editing Names up Significantly
Morgan Stanley Maintains Editas Medicine(EDIT.US) With Hold Rating, Cuts Target Price to $4
Morgan Stanley Remains a Hold on Editas Medicine (EDIT)
Evercore Upgrades Editas Medicine(EDIT.US) to Buy Rating, Maintains Target Price $7
Editas Medicine Upgraded to Outperform From In Line at Evercore ISI
Editas Medicine to Participate in Upcoming Investor Conferences
No Data
No Data